Vicore takes major step towards a clinical platform company targeting AT2R – new molecule ready for phase 1
· The new AT2R agonist C106, with patent protection to 2041, is ready to enter a phase 1 trial · Four additional AT2R agonists are expected to finalize preclinical evaluation during 2022 · R&D-day on March 10 with more details on Vicore’s research and development pipelineGothenburg, February 23, 2022 - Vicore Pharma Holding AB (publ) (“Vicore”), a clinical-stage pharmaceutical company developing medicines targeting the angiotensin II type 2 receptor (AT2R), today announces advancing its first new chemical entity from the VP03 program to a first in human phase 1 trial. This molecule is